Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis to acquire US BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences.

California-based BiPar specialises in the development of pioneering treatments for several different cancers through DNA repair using PARP (Poly ADP-Ribose Polymerase) inhibitors. BSI-201 enhances the effects of chemotherapy by preventing cancer cells from repairing their own DNA and therefore leading to the death of cancer cells.

BiPar's lead product candidate, BSI-201, is currently undergoing Phase 2 trials for the treatment of metastatic triple negative breast cancer and ovarian cancer among others.

Christopher A Viehbacher, CEO of sanofi-aventis said: "This acquisition illustrates our strong commitment to oncology to provide patients, physicians and public health stakeholders with breakthrough medicines addressing unmet medical needs".

Under the terms of the agreement, the final price of the deal depends on BSI-201 achieving milestone payments. The price could reach a maximum of $500m.

15th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics